Lesinidase alfa

Drug Profile

Lesinidase alfa

Alternative Names: Recombinant alpha-N-acetyl-glucosaminidase (rhNAGLU) - Alexion; SBC-103

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion Pharmaceuticals
  • Class Acetylglucosaminidases; Enzymes; Glycoside hydrolases; Recombinant proteins
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 12 Jan 2017 Alexion Pharmaceuticals completes a phase I/II clinical trials in Mucopolysaccharidosis III (In adolescents, In adults) in Netherlands (IV) (EudraCT2015-000753-20)
  • 16 Aug 2016 Phase-I/II clinical trials in Mucopolysaccharidosis III (In adolescents, In adults) in Netherlands (IV)
  • 14 Jul 2016 Preliminary efficacy and adverse events data from the brain MRI and neurocognitive assessments from a phase I/II trial in Mucopolysaccharidosis IIIB (In children) released by Alexion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top